Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Grants Accelerated Approval to Zanubrutinib for Marginal Zone Lymphoma

Approval is based on the results from the BGB-3111-214 and BGB-3111-AU-003 studies
20 Sep 2021
Anticancer agents & Biologic therapy;  Haematologic malignancies

On 14 September 2021, the US Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

Approval is based on two open-label, multicentre, single-arm studies: BGB-3111-214 (NCT03846427), which evaluated 66 patients with MZL who received at least one prior anti-CD20-based therapy, and BGB-3111-AU-003 (NCT02343120), which included 20 patients with previously treated MZL. Zanubrutinib was administered orally at 160 mg twice daily or 320 mg once daily.

The efficacy measures were overall response rate (ORR) and duration of response (DoR), as assessed by an independent review committee using the 2014 Lugano criteria.

In the first study, the CT-based ORR was 56% (95% confidence interval [CI] 43%, 68%), with 20% achieving complete responses (CR). In the second study, the ORR was 80% (95% CI 56%, 94%), with a CR rate of 20%.

The median DoR was not estimable; the estimated 1-year rate of DoR was 85% (95% CI 67, 93) and 72% (95% CI 40, 88), respectively.

The most common adverse reactions (≥30%) to zanubrutinib include decreased neutrophil count, upper respiratory tract infection, decreased platelet count, haemorrhage, decreased lymphocyte count, rash, and musculoskeletal pain. Serious adverse reactions occurred in 40% of patients with MZL, most often from pyrexia and pneumonia. The prescribing information includes warnings and precautions for haemorrhage, infections, cytopenias, second primary malignancies, and cardiac arrythmias.

The recommended zanubrutinib dosage is 160 mg orally twice daily or 320 mg orally once daily until disease progression or unacceptable toxicity.

Full prescribing information for Brukinsa is available here.

This indication is approved under accelerated approval based on ORR. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted priority review, Fast Track Designation and Orphan Designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.